Abstract
Transport of drugs across biological barriers has been a subject of study for decades. The discovery and characterization of proteins that confer the barrier properties of endothelia and epithelia, including tight junction proteins and membrane transporters belonging to the ATP-binding cassette (ABC) and Solute Carrier (SLC) families, represented a significant step forward into understanding the mechanisms that govern drug disposition. Subsequently, numerous studies, including both pre-clinical approaches and clinical investigations, have been carried out to determine the influence of physiological and pathological states on drug disposition. Importantly, there has been increasing interest in gaining a better understanding of drug disposition during pregnancy, since epidemiological and clinical studies have demonstrated that the use of medications by pregnant women is significant and this condition embodies a series of significant anatomical and physiological modifications, particularly at excretory organs and barrier sites (e.g., placenta, breast) expressing transporter proteins which influence pharmacokinetics. Currently, most of the research in this field has focused on the expression profiling of transporter proteins in trophoblasts and endothelial cells of the placenta, regulation of drug-resistance mechanisms in disease states and pharmacokinetic studies. However, little attention has been placed on the influence that the cerebrovascular dysfunction present in pregnancy-related disorders, such as preeclampsia, might exert on drug disposition in the mother’s brain. This issue is particularly important since recent findings have demonstrated that preeclamptic women suffer from long-term alterations in the integrity of the blood-brain barrier (BBB). In this review we aim to analyze the available evidence regarding the influence of pregnancy on the expression of transporters and TJ proteins in brain endothelial cells, as well the mechanisms that govern the pathophysiological alterations in the BBB of women who experience preeclampsia. Future research efforts should be focused not only on achieving a better understanding of the influence of preeclampsia-associated endothelial dysfunction on drug disposition, but also in optimizing the pharmacological treatments of women suffering pregnancy-related disorders, its comorbidities and to develop new therapies aiming to restore the integrity of the BBB.
Introduction
Worldwide, there has been an increase in the number of prescribed and over-the-counter medications taken by pregnant women (Mitchell et al., 2011; Beyene and Beza, 2018; Navaro et al., 2018). In Latin America, the true extent of the use of therapeutic drugs among pregnant women is not well characterized, but in countries such as Uruguay, 96% of pregnant women take medications and 78% use two or more (Viroga et al., 2013). A prospective cohort study conducted in Brazilian, Argentinian and Peruvian populations showed that immunodeficiency virus (HIV)-infected pregnant women exhibit a better adherence to anti-HIV therapy when compared to post-partum (Kreitchmann et al., 2012). The above-mentioned statistics are significant since pregnancy is a physiological condition associated with anatomical and physiological modifications capable of influencing the disposition of drugs, including increased blood volume, enhanced basal metabolism, and modified hormone levels, among others.
Treatment of chronic diseases within pregnancy carries a risk for both the mother and fetus, as the administered drug could cross the placenta and reach the fetus circulation, with deleterious consequences (Jentink et al., 2010; Tomson et al., 2018). Pharmacokinetic studies carried out in animal models and human suggest that exposure to drugs is reduced in pregnancy since there is an increase in both the renal glomerular filtration rate (thereby increasing renal elimination) and hepatic metabolism mediated by isoforms of cytochrome P450 enzymes and uridine 5′-phosphate glucuronosyltransferases (Pariente et al., 2016; Koren and Pariente, 2018). Furthermore, the expression and activity of transporters involved in drug disposition appears to be modified in excretory organs (Hebert et al., 2008) in a similar fashion to that observed with metabolizing enzymes.
Pregnant women suffering from psychiatric disorders and other central nervous system (CNS) diseases often require pharmacotherapy to stabilize their symptoms, which are likely to continue after labor due to their chronic nature. Clinical studies of pregnant women receiving antiepileptic and antidepressive pharmacotherapy demonstrated that the reduced drug exposure, due to increased clearance, is associated with an increase in the seizure rate (Reisinger et al., 2013) and decreased plasma levels of serotonin reuptake inhibitors, respectively (Westin et al., 2017). These outcomes clearly demonstrate that pregnancy could have a negative impact on the clinical effect of these drugs.
Furthermore, women under pharmacological treatment for epilepsy (Borthen, 2015) or depression (Palmsten et al., 2012) have a higher risk of suffering complications derived from pathophysiological alterations associated with pregnancy, such as preeclampsia. This pathological condition, that is present in 2–8% of all pregnancies (Duley, 2009), is a disorder characterized by hypertension and proteinuria after the twentieth gestational week, which may evolve to vasogenic edema, eclampsia (seizures) and cerebrovascular stroke if not properly controlled (American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy, 2013; Cipolla, 2013; Hammer and Cipolla, 2015). It is also reported that 75% of maternal deaths due to preeclampsia are related to cerebrovascular complications including eclampsia, intracranial hemorrhage, and edema (Zeeman, 2009).
Preeclampsia is associated with impaired systemic endothelial function (Roberts et al., 1989) and, in the brain of preeclamptic women, this endothelial dysfunction presents in the form of impaired integrity of the BBB (Bergman et al., 2018), which is apparently maintained even post-partum (Bergman et al., 2016). The influence of endothelial dysfunction on drug disposition in the brain has been studied in disease states, including stroke (Huang et al., 2017) however there is a lack of studies investigating the effect of endothelial dysfunction on brain drug disposition in pregnancy-related disorders. The latter issue is extremely important and needs to be addressed since preeclamptic women may need to receive medications to control symptoms within pregnancy, and/or at some point post-partum, particularly for treatment of chronic conditions, e.g., epilepsy, depression and HIV-infection. Furthermore, it is likely that women with brain endothelial dysfunction could experience increased exposure to the effects of endogenous factors and potentially harmful xenobiotics.
While the function of the BBB and transport of molecules across brain endothelial cells (BECs) has been extensively studied in non-pregnant populations, much less is known about BBB physiology during pregnancy and pregnancy-related disorders. Therefore, this review will summarize the findings related to the effect of pregnancy and preeclampsia on the expression and activity of proteins involved in the transport of drugs at the BBB.
Overview of the Blood-Brain Barrier
The BBB (Figure 1A) is a highly restrictive and specialized neurovascular network comprised of BECs, a basal membrane composed on collagen, fibronectin and laminin, pericytes, neurons and glial cells (Abbott, 2013; Daneman and Prat, 2015). In essence, the BBB isolates the brain parenchyma from the systemic circulation, regulating the supply of nutrients, controlling the bidirectional transport of endogenous mediators and protecting the CNS from exposure to harmful compounds, i.e., xenobiotics and metabolites.
FIGURE 1
Unlike other vascular beds, the endothelial cells of the BBB express a unique phenotype (Figure 1B) with higher levels of expression of tight junction (TJ) proteins, membrane transporters belonging to the ATP-binding cassette (ABC) and Solute Carrier families (SLC), and metabolizing enzymes (Decleves et al., 2011; Shawahna et al., 2011; Daneman and Prat, 2015; Liao et al., 2017).
Findings of in vitro and animal models have consistently demonstrated that the transport of molecules across the BBB is strongly regulated by membrane transporters and TJ proteins (Cecchelli et al., 1999; Cantrill et al., 2012; Helms et al., 2016). More recently, the use of imaging techniques and probes have allowed the in vivo analysis of transporter functionality, e.g., P-glycoprotein (P-GP) activity at the BBB in both healthy (Bauer et al., 2015) and disease states (Shin et al., 2016).
Overview of Tight Junction Proteins in Brain Endothelial Cells
The paracellular transport of molecules at the BBB is highly selective, and this feature is associated with the expression of high levels of TJ proteins. These proteins act as a biological adhesive, anchoring together adjacent BECs via transmembrane proteins attached to intracellular scaffolding proteins (Haseloff et al., 2015).
The transmembrane proteins occludin, claudins and Junctional Adhesion Molecules (JAMs) form complex strands that interact between cells, reducing paracellular diffusion (Haseloff et al., 2015; Keaney and Campbell, 2015). However, in order to maintain this restrictiveness, TJs are linked to the cytoplasmic zonula occludens (ZO) proteins that provide a structural bridge to the actin cytoskeleton. In zones where there is contact between three BECs, the TJ protein tricellulin (MARVELD2) plays a pivotal role in modulating paracellular permeability by reducing the passage of large molecules (Reinhold and Rittner, 2017).
Since the discovery that the permeability of the BBB could be regulated through reversible disruption of TJs, this principle has served as an approach for the delivery of therapeutics that would not cross this barrier by conventional means, e.g., passive diffusion, carrier-mediated transport (Dithmer et al., 2017; Sol et al., 2017).
Overview of Transporters Involved in Brain Drug Disposition
Data from in vitro and animal models have helped establish which membrane transporters impact brain drug disposition. Furthermore, the International Transporter Consortium et al. (2010) has published and updated recommendations (Hillgren et al., 2013) for decision-making processes related to drug-transporter interactions that could be translated to clinical settings. In this regard, the ABC transporters P-glycoprotein (P-GP; Cordon-Cardo et al., 1989), Multidrug Resistance-associated Proteins (MRPs) MRP4 and MRP5 (Huai-Yun et al., 1998; Seetharaman et al., 1998), Breast Cancer Resistance Protein (BCRP; Eisenblatter and Galla, 2002; Eisenblatter et al., 2003), and the Organic Anion Transporting Polypeptides (OATPs) OATP1A2 and OATP2B1 SLC transporters (Roth et al., 2012), are considered the most clinically important transporters within the BBB. Although there is evidence (from pre-clinical models) that other SLC transporters expressed in the BBB, including members of the Monocarboxylate Transporter (MCT; Lee and Kang, 2016), Organic Anion Transporter (OAT) subfamilies (Hosoya and Tachikawa, 2011) are involved in the uptake of drugs, this review will exclusively focus on the transporter proteins expressed in human BECs. The characteristics of these protein families in human BECs are briefly summarized in Table 1 and the following section.
Table 1
| Transporter | Gene | Molecular weight (kDa) | Detected at protein level | Localization and function | References |
|---|---|---|---|---|---|
| ABC | |||||
| P-GP | ABCB1 | 170 | Yes | Luminal/Efflux | Dauchy et al., 2009; Shawahna et al., 2011; Uchida et al., 2011 |
| BCRP | ABCG2 | 70 (Monomer) | Yes | Luminal/Efflux | Eisenblatter et al., 2003; Dauchy et al., 2009; Shawahna et al., 2011; Uchida et al., 2011 |
| MRPs | ABCC4 | 170 | Yes | Luminal/Efflux | Nies et al., 2004; Shawahna et al., 2011 |
| ABCC5 | 160 | Yes | |||
| SLC | |||||
| OATP1A2 | SLC21A3 | ≈70 | Yes | Luminal/Uptake | Lee et al., 2005; Roth et al., 2012 |
| OATP2B1 | SLC21A9 | ≈77 | Yes | Luminal/Uptake | Bronger et al., 2005; Roth et al., 2012 |
Human BEC ABC and SLC transporters involved in drug disposition.
ATP-Binding Cassette Transporters
P-glycoprotein is a 170 kDa efflux transporter encoded by the ABCB1 gene in human and the abcb1a/abcb1b genes in rodent. This protein is located at the luminal side of BECs and is described as a phenotypical marker (Sugawara et al., 1990; Dauchy et al., 2008; Cantrill et al., 2012). P-GP exhibits a broad substrate specificity that includes anticancer drugs (Mealey and Fidel, 2015), antidepressant drugs (O’Brien et al., 2012), antiepileptic drugs (Stepien et al., 2012), cardiotonic drugs (Ledwitch et al., 2016), HIV protease inhibitors (Liu et al., 2017) and immunosuppressants (Picchianti-Diamanti et al., 2014) among others. This characteristic implies the transporter has a predominant role in regulation the disposition of xenobiotics, including therapeutic drugs, thereby acting as a mechanism of detoxification and drug resistance. Some studies have also proposed a role for P-GP in the transport of endogenous mediators including steroids, bilirubin (Cascorbi, 2011) and amyloid-β, the peptide responsible of the formation of amyloid plaques in Alzheimer’s disease (Zhong et al., 2016).
The BCRP is an ABC transporter encoded by the ABCG2 gene in human and abcg2 gene in rodent, and is expressed at the luminal domain of BBB endothelial cells (Eisenblatter et al., 2003). BCRP is a monomeric protein (70 kDa) that requires the formation of at least a homodimer (and can even form homotetramers) to be functionally active (Ni et al., 2010). There is significant overlap in the substrate specificity of P-GP and BCRP and, like P-GP, BCRP can significantly influence drug transport in the body (Poguntke et al., 2010). In human BECs, BCRP is expressed at higher levels than P-GP (Shawahna et al., 2011; Uchida et al., 2011), but its overall contribution to the transport of substrates is less well understood than P-GP. As well as transporting drug substrates, BCRP also participates in transport of hormones (and conjugated metabolites) (Grube et al., 2018) and urate, a product of purine metabolism whose accumulation causes gout (Woodward et al., 2009; Fujita and Ichida, 2018).
The MRP transporters are encoded by the ABCC class of genes in human and abcc genes in rodents. MRPs mediate the transport of a diverse array of drugs and endogenous molecules including hormones, prostaglandins, leukotrienes and their conjugates (glucuronides, sulfates, and glutathione) (Zhou et al., 2008; Zhang et al., 2015; Bloise et al., 2016). Members of the MRP family are not as highly expressed in BECs as P-GP and BCRP in human BECs, but the findings of proteomic (Shawahna et al., 2011; Uchida et al., 2011) and transcriptomic (Warren et al., 2009) analyses have demonstrated that MRP4, an isoform located at the luminal side, is expressed at detectable levels in human BECs. Luminal expression of MRP5 in human BECs has also been confirmed by means of fluorescent immunohistochemistry (Nies et al., 2004).
Solute Carrier Transporters
The OATPs, a group of SLC transporters belonging to the SLCO subfamily, are ubiquitously expressed throughout the body, and at the human BBB, luminal expression of OATP1A2 (Lee et al., 2005) and OATP2B1 (Bronger et al., 2005), has been reported. OATPs mediate the uptake and efflux of endogenous and exogenous molecules, which tend to possess amphiphilic characteristics (Roth et al., 2012) and substrates include prostaglandins, steroid and thyroid hormone conjugates (Grube et al., 2018), bile acids and therapeutic drugs (Kalliokoski and Niemi, 2009; Roth et al., 2012).
Expression and Functionality of Blood-Brain Barrier Tight Junctions Proteins and Drug Transporters in Pregnancy
During normal pregnancy there is an increase in blood levels of several endogenous mediators including hormones and their metabolites, pro-inflammatory cytokines, chemokines, matrix metalloproteinases and growth factors (Chavan et al., 2017; Chen and Khalil, 2017). For example, clinical studies report that pro-inflammatory cytokines including interleukin-6(IL-6) and markers of cyclooxygenase-2 activity were increased in healthy women, suggesting that pregnancy is characterized by a mild, sub-clinical systemic inflammatory state (Palm et al., 2013; Danielsen et al., 2014). Under this physiological pro-inflammatory condition, expression and functionality of BBB TJ proteins and ABC/SLC transporters involved in drug disposition could be modified as is observed in other conditions (Keaney and Campbell, 2015; Qosa et al., 2015). Although little is known of the influence of pregnancy on the expression of BBB transporters and TJ proteins, recent studies are addressing this issue.
Tight Junction Proteins and Pregnancy
The influence of pregnancy on the integrity of TJs has primarily been studied in endothelial cells of the placenta (Marzioni et al., 2001; Ahn et al., 2015), and to date, we are not aware of any studies reporting the effects of a healthy pregnancy on the expression of TJ proteins in the maternal BBB. During normal pregnancy, high plasma levels of vascular endothelial growth factor (VEGF), an angiogenic mediator that increases BBB permeability through changes in the expression of TJ proteins (Lafuente et al., 2006) including claudin-5 and occludin (Argaw et al., 2012), have been reported (Evans et al., 1998). However, despite elevated plasma levels of VEGF, the permeability of the BBB remains unaltered in normal pregnancy (Cipolla, 2013). Indeed, studies have shown that the serum collected during late pregnancy attenuates the effects of VEGF on permeability of cerebral veins isolated from non-pregnant rats and rats in late-pregnancy (Schreurs et al., 2012). The authors attributed this outcome to the fact that, in late pregnancy, high plasma levels of soluble Fms-like tyrosine kinase 1 (sFlt1), a splice variant of the VEGF receptor (VEGFR) lacking activity, counteracts the effects of VEGF (Cipolla, 2013).
Membrane Transporters
Current evidence suggests that expression levels of ABC transporters within the maternal BBB vary throughout pregnancy, although this outcome has only been demonstrated in animal models. Studies report the expression of rodent P-gp and mrp1 in the BBB of pregnant mice is higher at mid-gestation and decreases in late-gestation (Coles et al., 2009), whilst positron emission tomography (PET) studies conducted on macaques (Chung et al., 2010) report that P-GP activity increased from mid-gestation to late-gestation, as evidenced by reduced accumulation of the radiolabelled P-GP substrate 11C-verapamil. However, the latter study did not confirm if this effect was a result of increased P-GP expression. No studies to date have reported the influence of pregnancy on the expression of SLC transporters in the maternal BBB, although it has been demonstrated expression of rodent Oatp1a4 (a rodent isoform that shows a high homology with human OATP1A2) in the BBB of the newborn increases with maturation (Harati et al., 2013).
ATP-binding cassette and SLC transporters govern movement of a whole array of endogenous and exogenous molecules through endothelial cells of the BBB. Consequently, this transcellular passage of substances may be significantly affected by pregnancy-dependent changes in transporter expression. However, despite the potential implications of modification of the barrier properties of the maternal BBB, to date, the precise mechanisms by which pregnancy could influence the expression of the above transporters are unclear and are only relatively recently being investigated.
A recent study reported that acute exposure of isolated hippocampal rat brain capillaries to serum obtained from pregnant rats reduced P-GP activity (Johnson et al., 2018). The authors hypothesized that this inhibition of P-GP, mediated by high levels of circulating serum factors, was associated with the increased incidence of seizures in normal pregnant rats. However, this study did not identify the molecules responsible for reduced P-GP activity. Furthermore, the findings are in contrast to those reported in studies investigating the relationship between seizures and P-GP activity, which suggest glutamate-mediated induction of cyclooxygenase-2 activity is responsible for the up-regulation of P-GP expression and activity in BECs in animal models of epilepsy (Zibell et al., 2009; van Vliet et al., 2010) and in capillaries isolated from human brains (Avemary et al., 2013). These findings are particularly important since studies suggest that in normal pregnancies and in preeclampsia, the cerebral levels of glutamate are reduced when compared to non-pregnant women (Nelander et al., 2018).
The specific effects of endogenous factors on the expression and activity of ABC transporters during pregnancy have been studied more in-depth on the developing fetal BBB than in the maternal BBB. Studies have reported that primary cultures of guinea pig BECs, obtained from late-gestational fetuses and postnatal pups, are highly responsive to the effects of glucocorticoids and pro-inflammatory cytokines, with hydrocortisone and dexamethasone (Iqbal et al., 2011) increasing P-gp activity and IL-1β, IL-6 and TNFα (Iqbal et al., 2012) decreasing P-gp activity. However, despite the opposing effects exerted by glucocorticoids and cytokines on P-gp expression and activity, a later report demonstrated that co-treatment with the synthetic glucocorticoid dexamethasone, apart from increasing the expression of the transporter, enhanced the inhibitory actions of IL-1β, IL-6, and TNFα on P-GP activity (Iqbal et al., 2016). The authors suggested that this enhancement of cytokine inhibitory actions is the result of a dexamethasone-mediated increase in the expression of pro-inflammatory cytokines receptors.
Transforming Growth Factor β (TGFβ), a protein found at high levels in plasma during pregnancy (Forbes and Westwood, 2010), has also been reported to regulate the expression of P-GP in BECs, and Baello et al. (2016), have reported TGFβ-mediated up-regulation of P-GP expression and activity, through activation of the ALK1 and ALK5 signaling pathways, in BECs isolated from male fetuses and postnatal guinea pig pups.
Endothelial Dysfunction at the Brain in Pregnancy-Related Disorders
Pregnancy alone can be considered as an inflammatory (but not pathological) state. One hallmark of pregnancy-related disorders, including preeclampsia, is the manifestation of endothelial dysfunction promoted by high levels of factors released from the placenta (Escudero et al., 2009; Myatt and Roberts, 2015).
The brain vasogenic edema present in later stages of preeclampsia is apparently the result of impaired autoregulation of cerebral blood flow and increased BBB permeability (Cipolla and Kraig, 2011; Cipolla, 2013; Hammer and Cipolla, 2015), but the pathophysiological mechanisms involved are still unclear. In vitro studies have demonstrated that when rat cerebral vasculature was exposed to plasma from normal and preeclamptic human pregnancies, there was an increase in BBB permeability. Interestingly, this effect was more marked following treatment with preeclamptic plasma (Amburgey et al., 2010). Furthermore, this study demonstrated that inhibition of VEGF receptor tyrosine kinase activity reversed the effect elicited by the treatment with preeclamptic plasma, suggesting that VEGF could be involved in modulating vascular permeability.
The pro-inflammatory cytokine TNFα is also believed to contribute to the increased BBB permeability in preeclampsia. TNFα infusion in healthy pregnant rats at gestational day 19 increased the water content in the anterior cerebrum without increasing the BBB permeability (Warrington et al., 2015). However, when pregnant rats were subjected to a reduction of uterine perfusion pressure (RUPP), a model of placental ischemia that emulates preeclampsia and impairs the maternal cerebral blood flow, they exhibited an increase in both the water content at the anterior cerebrum and BBB permeability, which was counteracted by treatment with the TNFα inhibitor etanercept.
Findings from other studies conducted in the RUPP model have helped to elucidate how BECs respond to the circulating factors present in preeclampsia. When RUPP was performed in pregnant rats at gestational day 14, edema and increased maternal BBB permeability in the anterior cerebrum were observed, with increased expression of the protein aquaporin 4 and no changes in the expression of TJ proteins (Warrington et al., 2014). However, it has been reported the same procedure led to post-partum edema and increased maternal BBB permeability in the posterior cortex, probably due to reduced expression of the TJ protein occludin (Clayton et al., 2018).
The increased BBB permeability reported by both Warrington et al. (2014) and Clayton et al. (2018), is partly supported by clinical studies which demonstrated that in women developing preeclampsia, blood levels of S100B, neuronal specific enolase (NSE) and neurofilament light chain (NfL), three markers of cerebral injury, were higher than those observed in women with normal pregnancies (Bergman et al., 2018). Indeed, another report showed that in preeclamptic women, the levels of S100B and NSE were still high 1-year post-partum, suggesting that the alterations in the integrity of the BBB are manifest for a substantial period of time following delivery (Bergman et al., 2016).
Pharmacological Management of Preeclampsia
Hypertension is one of the pathological features of preeclampsia and is routinely managed with the use of antihypertensive drugs including nifedipine, nicardipine, labetalol, hydralazine and methyldopa (Odigboegwu et al., 2018). Although it remains unclear whether the BBB permeability of these drugs is affected during preeclampsia, it is noteworthy that several antihypertensives, namely labetalol, nicardipine and nifedipine, are substrates of efflux transporters including P-GP (Thiel-Demby et al., 2009; Choi et al., 2013; Incecayir et al., 2013). The therapeutic management of neurological complications associated with preeclampsia, including seizures, primarily relies on the intravenous or intramuscular administration of magnesium sulfate, a drug with demonstrated ability to prevent the development of eclampsia and reduce maternal mortality (Altman et al., 2002).
The mechanism of action by which magnesium sulfate exerts its effects is unknown, but despite this limitation, it is widely considered a neuroprotective agent capable of reducing BBB permeability in animal models of brain injury (Li et al., 2017). Furthermore, a recent study demonstrated that magnesium sulfate reduced the water content in the anterior cerebrum, as well protein, cytokine, chemokine and VEGF levels in cerebrospinal fluid of rats subjected to the RUPP procedure (Zhang and Warrington, 2016). The above findings are important since the transport of drugs and endogenous mediators across the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, is a subject that is receiving increasing interest. A better characterization of the mechanisms that govern transport of molecules across this barrier will certainly help to understand brain drug disposition in both healthy and disease states such as preeclampsia.
To date, as the specific effects of magnesium sulfate on the expression/functionality of BBB TJ proteins and drug transporters are unknown, future studies addressing this subject will prove crucial in identifying potential therapeutic targets and in developing treatment strategies.
How Blood-Brain Barrier Endothelial Dysfunction Could Alter Brain Drug Disposition in Preeclampsia
The effect of endothelial dysfunction elicited by preeclampsia on brain drug disposition is unknown. A preeclampsia-mediated increase in BBB permeability could potentially result in increased permeation of endogenous, blood-borne substances, including placental derived sFlt-1, and hormones, into the brain. Furthermore, a less restrictive BBB could allow more extensive penetration of therapeutic drugs into the CNS, resulting in increased side effects. In preeclamptic women, in addition to hypertension, which is treated with antihypertensive P-GP drug substrates, comorbidities, including epilepsy, depression and HIV infection, are often reported (Pariente et al., 2016). Since there is evidence that drugs belonging to these pharmacological groups are substrates and/or of ABC/SLC transporters (O’Brien et al., 2012; Stepien et al., 2012; Alam et al., 2016; Han et al., 2017), there is an obvious need to better understand the effect of preeclampsia on BBB transporter physiology and the effects of transporter modifications on brain drug disposition. A list of drugs used for treatment of chronic diseases in pregnancy and preeclampsia is presented in Table 2.
Table 2
Drugs employed for treatment of chronic diseases in pregnancy and preeclampsia as substrates/inhibitors of ABC/SLC transporters expressed in human brain endothelial cells.
Although the precise mechanisms, and effects, of alterations in BBB permeability associated with preeclampsia have not yet been elucidated, it is possible to gain an insight into the potential consequences of BBB modification from clinical situations in which the expression of BBB drug transporters and BBB integrity are altered. In this regard, ischemic and hemorrhagic stroke are life-threatening conditions whose outcomes include severe BBB disruption (Knowland et al., 2014; Keep et al., 2018). In rodent models of ischemic stroke, based on middle cerebral artery occlusion (MCAO), an increase in brain water content and a decrease in the expression of TJ proteins, including occludin and claudin-5, have been observed (Huang et al., 2017). In functional terms, the cited reports demonstrated an increase in BBB permeability, i.e., increased brain levels of drugs transported through the paracellular pathway. Interestingly, MCAO also resulted in a time dependent up-regulation of P-GP expression (Cen et al., 2013; DeMars et al., 2017), which may serve as a compensatory protective mechanism, especially for drugs that are substrates of this transporter.
Pathological similarities are observed in both ischemic stroke and preeclampsia, including neuroinflammation, vasogenic edema and increased BBB permeability (Figure 2). To date, there is a lack of studies addressing the effect of preeclampsia on BBB physiology and, in particular, the effects of this disorder on TJ complexes, which govern paracellular permeability, and on ABC/SLC transporters, which regulate transcellular permeability. However, there is potential to monitor ABC transporter functionality, particularly P-GP activity, in women who have a history of preeclamptic pregnancies using non-invasive PET studies employing 11C-verapamil as tracer (Shin et al., 2016). Future studies could employ this technique in women who had suffered preeclampsia or eclampsia, in order to measure P-GP activity and investigate whether there is a correlation between transporter activity and propensity of seizures.
FIGURE 2
Concluding Remarks
The BBB is a highly restrictive but dynamic system that regulates the transport of ions and molecules into and out of the brain. Consequently, alterations in its function could result in an increased CNS exposure to potentially toxic xenobiotics, including therapeutic drugs, and endogenous factors. Given the findings that preeclampsia is associated with increased BBB permeability, there is an urgent and fundamental need to characterize the functionality of BBB ABC and SLC transporter proteins involved in CNS drug disposition through the use of appropriate pre-clinical models and execution of clinical studies.
A better understanding of preeclampsia-associated changes in BBB physiology would not only allow characterization of the processes responsible for pathophysiological changes, but could help improve the therapeutic management of women experiencing, or those who had experienced, preeclamptic pregnancies. Indeed, this knowledge will help to reduce the risk of acute and chronic complications caused by alterations in BBB function elicited by preeclampsia.
Statements
Author contributions
PT-V designed and wrote the manuscript. CE and JP contributed to the writing of the manuscript and provided a critical revision of its contents.
Acknowledgments
The authors would like to acknowledge the support from the Chilean National Commission of Science and Technological Research (CONICYT), which fund the project “Red multidisciplinaria para el análisis de los mecanismos fisiopatológicos subyacentes al daño endotelial cerebral presente en preeclampsia” Grant No. REDI170373.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbbottN. J. (2013). Blood-brain barrier structure and function and the challenges for CNS drug delivery.J. Inherit. Metab. Dis.36437–449. 10.1007/s10545-013-9608-0
2
AbbottN. J.PatabendigeA. A.DolmanD. E.YusofS. R.BegleyD. J. (2010). Structure and function of the blood-brain barrier.Neurobiol. Dis.3713–25. 10.1016/j.nbd.2009.07.030
3
AhnC.YangH.LeeD.AnB. S.JeungE. B. (2015). Placental claudin expression and its regulation by endogenous sex steroid hormones.Steroids10044–51. 10.1016/j.steroids.2015.05.001
4
AlamC.Whyte-AllmanS. K.OmeragicA.BendayanR. (2016). Role and modulation of drug transporters in HIV-1 therapy.Adv. Drug Deliv. Rev.103121–143. 10.1016/j.addr.2016.05.001
5
AltmanD.CarroliG.DuleyL.FarrellB.MoodleyJ.NeilsonJ.et al (2002). Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.Lancet3591877–1890. 10.1016/S0140-6736(02)08778-0
6
AmburgeyO. A.ChapmanA. C.MayV.BernsteinI. M.CipollaM. J. (2010). Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling.Hypertension561003–1008. 10.1161/HYPERTENSIONAHA.110.158931
7
AnnaertP.YeZ. W.StiegerB.AugustijnsP. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Xenobiotica40163–176. 10.3109/00498250903509375
8
Antunes NdeJ.Wichert-AnaL.CoelhoE. B.Della PasquaO.Alexandre JuniorV.TakayanaguiO. M.et al (2016). Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.Eur. J. Clin. Pharmacol.72195–201. 10.1007/s00228-015-1970-4
9
American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy (2013). Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy.Obstet. Gynecol.1221122–1131.
10
ArgawA. T.AspL.ZhangJ.NavrazhinaK.PhamT.MarianiJ. N.et al (2012). Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease.J. Clin. Invest.1222454–2468. 10.1172/JCI60842
11
AvemaryJ.SalvamoserJ. D.PeraudA.RemiJ.NoachtarS.FrickerG.et al (2013). Dynamic regulation of P-glycoprotein in human brain capillaries.Mol. Pharm.103333–3341. 10.1021/mp4001102
12
BaelloS.IqbalM.GibbW.MatthewsS. G. (2016). Astrocyte-mediated regulation of multidrug resistance p-glycoprotein in fetal and neonatal brain endothelial cells: age-dependent effects.Physiol. Rep.4:e12853. 10.14814/phy2.12853
13
BauerM.KarchR.ZeitlingerM.PhilippeC.RomermannK.StanekJ.et al (2015). Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.J. Cereb. Blood Flow Metab.35743–746. 10.1038/jcbfm.2015.19
14
BergmanL.AkerudH.WikstromA. K.LarssonM.NaessenT.AkhterT. (2016). Cerebral biomarkers in women with preeclampsia are still elevated 1 year postpartum.Am. J. Hypertens.291374–1379. 10.1093/ajh/hpw097
15
BergmanL.ZetterbergH.KaiholaH.HagbergH.BlennowK.AkerudH. (2018). Blood-based cerebral biomarkers in preeclampsia: plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study.PLoS One13:e0196025. 10.1371/journal.pone.0196025
16
BeyeneK. G.BezaS. W. (2018). Self-medication practice and associated factors among pregnant women in Addis Ababa, Ethiopia.Trop. Med. Health46:10. 10.1186/s41182-018-0091-z
17
BloiseE.Ortiga-CarvalhoT. M.ReisF. M.LyeS. J.GibbW.MatthewsS. G. (2016). ATP-binding cassette transporters in reproduction: a new frontier.Hum. Reprod. Update22164–181. 10.1093/humupd/dmv049
18
BorthenI. (2015). Obstetrical complications in women with epilepsy.Seizure2832–34. 10.1016/j.seizure.2015.02.018
19
BrongerH.KonigJ.KopplowK.SteinerH. H.AhmadiR.Herold-MendeC.et al (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.Cancer Res.6511419–11428. 10.1158/0008-5472.CAN-05-1271
20
CampbellS. D.GadelS.FriedelC.CraffordA.ReginaK. J.KharaschE. D. (2015). Influence of HIV antiretrovirals on methadone N-demethylation and transport.Biochem. Pharmacol.95115–125. 10.1016/j.bcp.2015.03.007
21
CantrillC. A.SkinnerR. A.RothwellN. J.PennyJ. I. (2012). An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro blood-brain barrier model.Brain Res.147917–30. 10.1016/j.brainres.2012.08.031
22
CascorbiI. (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations.Handb. Exp. Pharmacol.201261–283. 10.1007/978-3-642-14541-4_6
23
CecchelliR.DehouckB.DescampsL.FenartL.Buee-ScherrerV. V.DuhemC.et al (1999). In vitro model for evaluating drug transport across the blood-brain barrier.Adv. Drug Deliv. Rev.36165–178. 10.1016/S0169-409X(98)00083-0
24
CenJ.LiuL.LiM. S.HeL.WangL. J.LiuY. Q.et al (2013). Alteration in P-glycoprotein at the blood-brain barrier in the early period of MCAO in rats.J. Pharm. Pharmacol.65665–672. 10.1111/jphp.12033
25
ChavanA. R.GriffithO. W.WagnerG. P. (2017). The inflammation paradox in the evolution of mammalian pregnancy: turning a foe into a friend.Curr. Opin. Genet. Dev.4724–32. 10.1016/j.gde.2017.08.004
26
ChenJ.KhalilR. A. (2017). Matrix metalloproteinases in normal pregnancy and preeclampsia.Prog. Mol. Biol. Transl. Sci.14887–165. 10.1016/bs.pmbts.2017.04.001
27
ChoiJ. S.ChoiI.ChoiD. H. (2013). Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.Pharmacol. Rep.651422–1430. 10.1016/S1734-1140(13)71502-0
28
ChungF. S.EyalS.MuziM.LinkJ. M.MankoffD. A.KaddoumiA.et al (2010). Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate.Br. J. Pharmacol.159394–404. 10.1111/j.1476-5381.2009.00538.x
29
CipollaM. J. (2013). The adaptation of the cerebral circulation to pregnancy: mechanisms and consequences.J. Cereb. Blood Flow Metab.33465–478. 10.1038/jcbfm.2012.210
30
CipollaM. J.KraigR. P. (2011). Seizures in women with preeclampsia: mechanisms and management.Fetal Matern. Med. Rev.2291–108. 10.1017/S0965539511000040
31
ClaytonA. M.ShaoQ.PaauwN. D.GiambroneA. B.GrangerJ. P.WarringtonJ. P. (2018). Postpartum increases in cerebral edema and inflammation in response to placental ischemia during pregnancy.Brain Behav. Immun.70376–389. 10.1016/j.bbi.2018.03.028
32
ColesL. D.LeeI. J.HassanH. E.EddingtonN. D. (2009). Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice.J. Pharm. Sci.982832–2846. 10.1002/jps.21644
33
Cordon-CardoC.O’brienJ. P.CasalsD.Rittman-GrauerL.BiedlerJ. L.MelamedM. R.et al (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proc. Natl. Acad. Sci. U.S.A.86695–698. 10.1073/pnas.86.2.695
34
DanemanR.PratA. (2015). The blood-brain barrier.Cold Spring Harb. Perspect. Biol.7:a020412. 10.1101/cshperspect.a020412
35
DanielsenI.GranstromC.RytterD.HalldorssonT. I.BechB. H.HenriksenT. B.et al (2014). Subclinical inflammation during third trimester of pregnancy was not associated with markers of the metabolic syndrome in young adult offspring.Obesity221351–1358. 10.1002/oby.20650
36
DauchyS.DutheilF.WeaverR. J.ChassouxF.Daumas-DuportC.CouraudP. O.et al (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier.J. Neurochem.1071518–1528. 10.1111/j.1471-4159.2008.05720.x
37
DauchyS.MillerF.CouraudP. O.WeaverR. J.WekslerB.RomeroI. A.et al (2009). Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells.Biochem. Pharmacol.77897–909. 10.1016/j.bcp.2008.11.001
38
DeclevesX.JacobA.YousifS.ShawahnaR.PotinS.ScherrmannJ. M. (2011). Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier.Curr. Drug Metab.12732–741. 10.2174/138920011798357024
39
DeMarsK. M.YangC.HawkinsK. E.MccreaA. O.SiwarskiD. M.Candelario-JalilE. (2017). Spatiotemporal changes in P-glycoprotein levels in brain and peripheral tissues following ischemic stroke in rats.J. Exp. Neurosci.11:1179069517701741. 10.1177/1179069517701741
40
DithmerS.StaatC.MullerC.KuM. C.PohlmannA.NiendorfT.et al (2017). Claudin peptidomimetics modulate tissue barriers for enhanced drug delivery.Ann. N. Y. Acad. Sci.1397169–184. 10.1111/nyas.13359
41
DuleyL. (2009). The global impact of pre-eclampsia and eclampsia.Semin. Perinatol.33130–137. 10.1053/j.semperi.2009.02.010
42
EisenblatterT.GallaH. J. (2002). A new multidrug resistance protein at the blood-brain barrier.Biochem. Biophys. Res. Commun.2931273–1278. 10.1016/S0006-291X(02)00376-5
43
EisenblatterT.HuwelS.GallaH. J. (2003). Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.Brain Res.971221–231. 10.1016/S0006-8993(03)02401-6
44
EscuderoC.PueblaC.WestermeierF.SobreviaL. (2009). Potential cell signalling mechanisms involved in differential placental angiogenesis in mild and severe pre-eclampsia.Curr. Vasc. Pharmacol.7475–485. 10.2174/157016109789043865
45
EvansP. W.WheelerT.AnthonyF. W.OsmondC. (1998). A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy.Hum. Reprod.131057–1062. 10.1093/humrep/13.4.1057
46
ForbesK.WestwoodM. (2010). Maternal growth factor regulation of human placental development and fetal growth.J. Endocrinol.2071–16. 10.1677/JOE-10-0174
47
FujimotoH.HiguchiM.WatanabeH.KohY.GhoshA. K.MitsuyaH.et al (2009). P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.Biol. Pharm. Bull.321588–1593. 10.1248/bpb.32.1588
48
FujitaK.IchidaK. (2018). ABCG2 as a therapeutic target candidate for gout.Expert Opin. Ther. Targets22123–129. 10.1080/14728222.2018.1420167
49
GrubeM.HagenP.JedlitschkyG. (2018). Neurosteroid transport in the brain: role of ABC and SLC transporters.Front. Pharmacol.9:354. 10.3389/fphar.2018.00354
50
GuptaA.ZhangY.UnadkatJ. D.MaoQ. (2004). HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).J. Pharmacol. Exp. Ther.310334–341. 10.1124/jpet.104.065342
51
HammerE. S.CipollaM. J. (2015). Cerebrovascular dysfunction in preeclamptic pregnancies.Curr. Hypertens. Rep.17:64. 10.1007/s11906-015-0575-8
52
HanH.MannA.EksteinD.EyalS. (2017). Breaking bad: the structure and function of the blood-brain barrier in epilepsy.AAPS J.19973–988. 10.1208/s12248-017-0096-2
53
HaratiR.BenechH.VillegierA. S.MabondzoA. (2013). P-glycoprotein, breast cancer resistance protein, Organic Anion Transporter 3, and Transporting Peptide 1a4 during blood-brain barrier maturation: involvement of Wnt/beta-catenin and endothelin-1 signaling.Mol. Pharm.101566–1580. 10.1021/mp300334r
54
HartkoornR. C.KwanW. S.ShallcrossV.ChaikanA.LiptrottN.EganD.et al (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.Pharmacogenet. Genomics20112–120. 10.1097/FPC.0b013e328335b02d
55
HaseloffR. F.DithmerS.WinklerL.WolburgH.BlasigI. E. (2015). Transmembrane proteins of the tight junctions at the blood-brain barrier: structural and functional aspects.Semin. Cell Dev. Biol.3816–25. 10.1016/j.semcdb.2014.11.004
56
HashiguchiY.HamadaA.ShinoharaT.TsuchiyaK.JonoH.SaitoH. (2013). Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.Biochem. Biophys. Res. Commun.439221–227. 10.1016/j.bbrc.2013.08.054
57
HebertM. F.EasterlingT. R.KirbyB.CarrD. B.BuchananM. L.RutherfordT.et al (2008). Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.Clin. Pharmacol. Ther.84248–253. 10.1038/clpt.2008.1
58
HelmsH. C.AbbottN. J.BurekM.CecchelliR.CouraudP. O.DeliM. A.et al (2016). In vitro models of the blood-brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use.J. Cereb. Blood Flow Metab.36862–890. 10.1177/0271678X16630991
59
HillgrenK. M.KepplerD.ZurA. A.GiacominiK. M.StiegerB.CassC. E.et al (2013). Emerging transporters of clinical importance: an update from the International Transporter Consortium.Clin. Pharmacol. Ther.9452–63. 10.1038/clpt.2013.74
60
HosoyaK.TachikawaM. (2011). Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins.Clin. Exp. Nephrol.15478–485. 10.1007/s10157-011-0460-y
61
Huai-YunH.SecrestD. T.MarkK. S.CarneyD.BrandquistC.ElmquistW. F.et al (1998). Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells.Biochem. Biophys. Res. Commun.243816–820. 10.1006/bbrc.1997.8132
62
HuangL.ShangE.FanW.LiX.LiB.HeS.et al (2017). S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.Eur. J. Pharm. Sci.10940–47. 10.1016/j.ejps.2017.07.029
63
IncecayirT.TsumeY.AmidonG. L. (2013). Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.Mol. Pharm.10958–966. 10.1021/mp300410n
64
International Transporter Consortium GiacominiGiacominiK. M.HuangS. M.TweedieD. J.BenetL. Z.BrouwerK. L.et al (2010). Membrane transporters in drug development.Nat. Rev. Drug Discov.9215–236. 10.1038/nrd3028
65
IqbalM.BaelloS.JavamM.AudetteM. C.GibbW.MatthewsS. G. (2016). Regulation of multidrug resistance P-glycoprotein in the developing blood-brain barrier: interplay between glucocorticoids and cytokines.J. Neuroendocrinol.28:12360. 10.1111/jne.12360
66
IqbalM.GibbW.MatthewsS. G. (2011). Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier.Endocrinology1521067–1079. 10.1210/en.2010-1227
67
IqbalM.HoH. L.PetropoulosS.MoisiadisV. G.GibbW.MatthewsS. G. (2012). Pro-inflammatory cytokine regulation of P-glycoprotein in the developing blood-brain barrier.PLoS One7:e43022. 10.1371/journal.pone.0043022
68
JannehO.JonesE.ChandlerB.OwenA.KhooS. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.J. Antimicrob. Chemother.60987–993. 10.1093/jac/dkm353
69
JannehO.OwenA.ChandlerB.HartkoornR. C.HartC. A.BrayP. G.et al (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.AIDS192097–2102. 10.1097/01.aids.0000194793.36175.40
70
JentinkJ.LoaneM. A.DolkH.BarisicI.GarneE.MorrisJ. K.et al (2010). Valproic acid monotherapy in pregnancy and major congenital malformations.N. Engl. J. Med.3622185–2193. 10.1056/NEJMoa0907328
71
JohnsonA. C.HammerE. S.SakkakiS.TrembleS. M.HolmesG. L.CipollaM. J. (2018). Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: role of circulating factors.Brain Behav. Immun.6713–23. 10.1016/j.bbi.2017.07.017
72
KadonoK.AkabaneT.TabataK.GatoK.TerashitaS.TeramuraT. (2010). Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.Drug Metab. Dispos.381230–1237. 10.1124/dmd.109.029322
73
KalliokoskiA.NiemiM. (2009). Impact of OATP transporters on pharmacokinetics.Br. J. Pharmacol.158693–705. 10.1111/j.1476-5381.2009.00430.x
74
KeaneyJ.CampbellM. (2015). The dynamic blood-brain barrier.FEBS J.2824067–4079. 10.1111/febs.13412
75
KeepR. F.AndjelkovicA. V.XiangJ.StamatovicS. M.AntonettiD. A.HuaY.et al (2018). Brain endothelial cell junctions after cerebral hemorrhage: changes, mechanisms and therapeutic targets.J. Cereb. Blood Flow Metab.381255–1275. 10.1177/0271678X18774666
76
KimR. B.FrommM. F.WandelC.LeakeB.WoodA. J.RodenD. M.et al (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.J. Clin. Invest.101289–294. 10.1172/JCI1269
77
KisO.ZastreJ. A.RamaswamyM.BendayanR. (2010). pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug–drug interactions.J. Pharmacol. Exp. Ther.3341009–1022. 10.1124/jpet.110.166314
78
KnowlandD.AracA.SekiguchiK. J.HsuM.LutzS. E.PerrinoJ.et al (2014). Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke.Neuron82603–617. 10.1016/j.neuron.2014.03.003
79
KorenG.ParienteG. (2018). Pregnancy- associated changes in pharmacokinetics and their clinical implications.Pharm. Res.35:61. 10.1007/s11095-018-2352-2
80
KreitchmannR.HarrisD. R.KakehasiF.HabererJ. E.CahnP.LossoM.et al (2012). Antiretroviral adherence during pregnancy and postpartum in Latin America.AIDS Patient Care STDS26486–495. 10.1089/apc.2012.0013
81
LafuenteJ. V.ArgandonaE. G.MitreB. (2006). VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers.J. Neural Transm.113487–496. 10.1007/s00702-005-0407-0
82
LedwitchK. V.BarnesR. W.RobertsA. G. (2016). Unravelling the complex drug-drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein.Biosci. Rep.36:e00309. 10.1042/BSR20150317
83
LeeC. G.GottesmanM. M.CardarelliC. O.RamachandraM.JeangK. T.AmbudkarS. V.et al (1998). HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.Biochemistry373594–3601. 10.1021/bi972709x
84
LeeN. Y.KangY. S. (2016). In vivo and in vitro evidence for brain uptake of 4-phenylbutyrate by the monocarboxylate transporter 1 (MCT1).Pharm. Res.331711–1722. 10.1007/s11095-016-1912-6
85
LeeW.GlaeserH.SmithL. H.RobertsR. L.MoeckelG. W.GervasiniG.et al (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry.J. Biol. Chem.2809610–9617. 10.1074/jbc.M411092200
86
LiX.HanX.YangJ.BaoJ.DiX.ZhangG.et al (2017). Magnesium sulfate provides neuroprotection in eclampsia-like seizure model by ameliorating neuroinflammation and brain edema.Mol. Neurobiol.547938–7948. 10.1007/s12035-016-0278-4
87
LiaoM. Z.GaoC.ShiremanL. M.PhillipsB.RislerL. J.NeradugommaN. K.et al (2017). P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.Pharmacol. Res.11961–71. 10.1016/j.phrs.2017.01.018
88
LiuX.MaQ.ZhaoY.MuW.SunX.ChengY.et al (2017). Impact of single nucleotide polymorphisms on plasma concentrations of efavirenz and lopinavir/ritonavir in Chinese children infected with the human immunodeficiency virus.Pharmacotherapy371073–1080. 10.1002/phar.1988
89
Luna-TortosC.FedrowitzM.LoscherW. (2008). Several major antiepileptic drugs are substrates for human P-glycoprotein.Neuropharmacology551364–1375. 10.1016/j.neuropharm.2008.08.032
90
MarzioniD.BanitaM.FeliciA.ParadinasF. J.NewlandsE.De NictolisM.et al (2001). Expression of ZO-1 and occludin in normal human placenta and in hydatidiform moles.Mol. Hum. Reprod.7279–285. 10.1093/molehr/7.3.279
91
MealeyK. L.FidelJ. (2015). P-glycoprotein mediated drug interactions in animals and humans with cancer.J. Vet. Intern. Med.291–6. 10.1111/jvim.12525
92
MitchellA. A.GilboaS. M.WerlerM. M.KelleyK. E.LouikC.Hernandez-DiazS.et al (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.Am. J. Obstet. Gynecol.205e51–e58. 10.1016/j.ajog.2011.02.029
93
MyattL.RobertsJ. M. (2015). Preeclampsia: syndrome or disease?Curr. Hypertens. Rep.17:83. 10.1007/s11906-015-0595-4
94
NavaroM.VezzosiL.SantagatiG.AngelilloI. F.Collaborative WorkingG. (2018). Knowledge, attitudes, and practice regarding medication use in pregnant women in Southern Italy.PLoS One13:e0198618. 10.1371/journal.pone.0198618
95
NelanderM.WikstromA. K.WeisJ.BergmanL.LarssonA.Sundstrom-PoromaaI.et al (2018). Cerebral osmolytes and plasma osmolality in pregnancy and preeclampsia: a proton magnetic resonance spectroscopy study.Am. J. Hypertens.31847–853. 10.1093/ajh/hpy019
96
NiZ.BikadiZ.RosenbergM. F.MaoQ. (2010). Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Curr. Drug Metab.11603–617. 10.2174/138920010792927325
97
NiesA. T.JedlitschkyG.KonigJ.Herold-MendeC.SteinerH. H.SchmittH. P.et al (2004). Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain.Neuroscience129349–360. 10.1016/j.neuroscience.2004.07.051
98
O’BrienF. E.ClarkeG.DinanT. G.CryanJ. F.GriffinB. T. (2013). Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.Int. J. Neuropsychopharmacol.162259–2272. 10.1017/S1461145713000692
99
O’BrienF. E.DinanT. G.GriffinB. T.CryanJ. F. (2012). Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.Br. J. Pharmacol.165289–312. 10.1111/j.1476-5381.2011.01557.x
100
OdigboegwuO.PanL. J.ChatterjeeP. (2018). Use of antihypertensive drugs during preeclampsia.Front. Cardiovasc. Med.5:50. 10.3389/fcvm.2018.00050
101
PalmM.AxelssonO.WernrothL.LarssonA.BasuS. (2013). Involvement of inflammation in normal pregnancy.Acta Obstet. Gynecol. Scand.92601–605. 10.1111/aogs.12093
102
PalmstenK.SetoguchiS.MargulisA. V.PatrickA. R.Hernandez-DiazS. (2012). Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?Am. J. Epidemiol.175988–997. 10.1093/aje/kwr394
103
PanG.GiriN.ElmquistW. F. (2007). Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.Drug Metab. Dispos.351165–1173. 10.1124/dmd.106.014274
104
ParienteG.LeibsonT.CarlsA.Adams-WebberT.ItoS.KorenG. (2016). Pregnancy-associated changes in pharmacokinetics: a systematic review.PLoS Med.13:e1002160. 10.1371/journal.pmed.1002160
105
PerloffE. S.DuanS. X.SkolnikP. R.GreenblattD. J.Von MoltkeL. L. (2005). Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.Drug Metab. Dispos.33764–770. 10.1124/dmd.104.002931
106
Picchianti-DiamantiA.RosadoM. M.ScarsellaM.LaganaB.D’amelioR. (2014). P-glycoprotein and drug resistance in systemic autoimmune diseases.Int. J. Mol. Sci.154965–4976. 10.3390/ijms15034965
107
PoguntkeM.HazaiE.FrommM. F.ZolkO. (2010). Drug transport by breast cancer resistance protein.Expert Opin. Drug Metab. Toxicol.61363–1384. 10.1517/17425255.2010.519700
108
QosaH.MillerD. S.PasinelliP.TrottiD. (2015). Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.Brain Res.1628298–316. 10.1016/j.brainres.2015.07.005
109
ReinholdA. K.RittnerH. L. (2017). Barrier function in the peripheral and central nervous system-a review.Pflugers Arch.469123–134. 10.1007/s00424-016-1920-8
110
ReisingerT. L.NewmanM.LoringD. W.PennellP. B.MeadorK. J. (2013). Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.Epilepsy Behav.2913–18. 10.1016/j.yebeh.2013.06.026
111
RobertsJ. M.TaylorR. N.MusciT. J.RodgersG. M.HubelC. A.MclaughlinM. K. (1989). Preeclampsia: an endothelial cell disorder.Am. J. Obstet. Gynecol.1611200–1204. 10.1016/0002-9378(89)90665-0
112
RomermannK.HelmerR.LoscherW. (2015). The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).Neuropharmacology937–14. 10.1016/j.neuropharm.2015.01.015
113
RothM.ObaidatA.HagenbuchB. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.Br. J. Pharmacol.1651260–1287. 10.1111/j.1476-5381.2011.01724.x
114
SchreursM. P.HoustonE. M.MayV.CipollaM. J. (2012). The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy.FASEB J.26355–362. 10.1096/fj.11-191916
115
SchuetzJ. D.ConnellyM. C.SunD.PaibirS. G.FlynnP. M.SrinivasR.V.et al (1999). MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs.Nat. Med.51048–1051. 10.1038/12487
116
SeetharamanS.BarrandM. A.MaskellL.ScheperR. J. (1998). Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates.J. Neurochem.701151–1159. 10.1046/j.1471-4159.1998.70031151.x
117
ShawahnaR.UchidaY.DeclevesX.OhtsukiS.YousifS.DauchyS.et al (2011). Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.Mol. Pharm.81332–1341. 10.1021/mp200129p
118
ShinJ. W.ChuK.ShinS. A.JungK. H.LeeS. T.LeeY. S.et al (2016). Clinical applications of simultaneous PET/MR imaging using (R)-[11C]-verapamil with cyclosporin a: preliminary results on a surrogate marker of drug-resistant epilepsy.AJNR Am. J. Neuroradiol.37600–606. 10.3174/ajnr.A4566
119
SolY.ChoiS. H.KimH. J.KimY. W.ChoB. M.HanH. S.et al (2017). Morphologic mechanisms of increased vascular permeability of triolein emulsion to the blood-brain barrier.Microscopy66366–370. 10.1093/jmicro/dfx026
120
StepienK. M.TomaszewskiM.TomaszewskaJ.CzuczwarS. J. (2012). The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs.Pharmacol. Rep.641011–1019. 10.1016/S1734-1140(12)70900-3
121
StorchC. H.TheileD.LindenmaierH.HaefeliW. E.WeissJ. (2007). Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.Biochem. Pharmacol.731573–1581. 10.1016/j.bcp.2007.01.027
122
SugawaraI.HamadaH.TsuruoT.MoriS. (1990). Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord.Jpn. J. Cancer Res.81727–730. 10.1111/j.1349-7006.1990.tb02636.x
123
Thiel-DembyV. E.HumphreysJ. E.St John WilliamsL. A.EllensH. M.ShahN.AyrtonA. D.et al (2009). Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.Mol. Pharm.611–18. 10.1021/mp800122b
124
TomsonT.BattinoD.BonizzoniE.CraigJ.LindhoutD.PeruccaE.et al (2018). Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.Lancet Neurol.17530–538. 10.1016/S1474-4422(18)30107-8
125
UchidaY.OhtsukiS.KatsukuraY.IkedaC.SuzukiT.KamiieJ.et al (2011). Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.J. Neurochem.117333–345. 10.1111/j.1471-4159.2011.07208.x
126
Van Der SandtI. C.VosC. M.NabulsiL.Blom-RoosemalenM. C.VoorwindenH. H.de BoerA. G.et al (2001). Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier.AIDS15483–491. 10.1097/00002030-200103090-00007
127
van VlietE. A.ZibellG.PekcecA.SchlichtigerJ.EdelbroekP. M.HoltmanL.et al (2010). COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.Neuropharmacology58404–412. 10.1016/j.neuropharm.2009.09.012
128
VirogaS.LópezM.TamosiunasG. (2013). Seguridad de los medicamentos gastrointestinales en el embarazo.Arch. Med. Interna3549–54.
129
WangX.FurukawaT.NitandaT.OkamotoM.SugimotoY.AkiyamaS.et al (2003). Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.Mol. Pharmacol.6365–72. 10.1124/mol.63.1.65
130
WarrenM. S.ZerangueN.WoodfordK.RobertsL. M.TateE. H.FengB.et al (2009). Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human.Pharmacol. Res.59404–413. 10.1016/j.phrs.2009.02.007
131
WarringtonJ. P.DrummondH. A.GrangerJ. P.RyanM. J. (2015). Placental ischemia-induced increases in brain water content and cerebrovascular permeability: role of TNF-alpha.Am. J. Physiol. Regul. Integr. Comp. Physiol.309R1425–R1431. 10.1152/ajpregu.00372.2015
132
WarringtonJ. P.FanF.MurphyS. R.RomanR. J.DrummondH. A.GrangerJ. P.et al (2014). Placental ischemia in pregnant rats impairs cerebral blood flow autoregulation and increases blood-brain barrier permeability.Physiol. Rep.2:e12134. 10.14814/phy2.12134
133
WeissJ.DormannS. M.Martin-FacklamM.KerpenC. J.Ketabi-KiyanvashN.HaefeliW. E. (2003a). Inhibition of P-glycoprotein by newer antidepressants.J. Pharmacol. Exp. Ther.305197–204. 10.1124/jpet.102.046532
134
WeissJ.KerpenC. J.LindenmaierH.DormannS. M.HaefeliW. E. (2003b). Interaction of antiepileptic drugs with human P-glycoprotein in vitro.J. Pharmacol. Exp. Ther.307262–267. 10.1124/jpet.103.054197
135
WeissJ.RoseJ.StorchC. H.Ketabi-KiyanvashN.SauerA.HaefeliW. E.EfferthT. (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.J. Antimicrob. Chemother.59238–245. 10.1093/jac/dkl474
136
WestinA. A.BrekkeM.MoldenE.SkogvollE.SpigsetO. (2017). Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition.PLoS One12:e0181082. 10.1371/journal.pone.0181082
137
WoodwardO. M.KottgenA.CoreshJ.BoerwinkleE.GugginoW. B.KottgenM. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.Proc. Natl. Acad. Sci. U.S.A.10610338–10342. 10.1073/pnas.0901249106
138
ZeemanG. G. (2009). Neurologic complications of pre-eclampsia.Semin. Perinatol.33166–172. 10.1053/j.semperi.2009.02.003
139
ZhangC.KwanP.ZuoZ.BaumL. (2012). The transport of antiepileptic drugs by P-glycoprotein.Adv. Drug Deliv. Rev.64930–942. 10.1016/j.addr.2011.12.003
140
ZhangC.ZuoZ.KwanP.BaumL. (2011). In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein.Epilepsia521894–1904. 10.1111/j.1528-1167.2011.03140.x
141
ZhangL. W.WarringtonJ. P. (2016). Magnesium sulfate prevents placental ischemia-induced increases in brain water content and cerebrospinal fluid cytokines in pregnant rats.Front. Neurosci.10:561. 10.3389/fnins.2016.00561
142
ZhangY. K.WangY. J.GuptaP.ChenZ. S. (2015). Multidrug resistance proteins (MRPs) and cancer therapy.AAPS J.17802–812. 10.1208/s12248-015-9757-1
143
ZhongX.LiuM. Y.SunX. H.WeiM. J. (2016). Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis.Sci. Rep.6:32708. 10.1038/srep32708
144
ZhouS. F.WangL. L.DiY. M.XueC. C.DuanW.LiC. G.et al (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.Curr. Med. Chem.151981–2039. 10.2174/092986708785132870
145
ZibellG.UnkruerB.PekcecA.HartzA. M.BauerB.MillerD. S.et al (2009). Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition.Neuropharmacology56849–855. 10.1016/j.neuropharm.2009.01.009
Summary
Keywords
blood-brain barrier, ABC transporters, SLC transporters, tight junction proteins, endothelial dysfunction, preeclampsia, eclampsia, brain alterations
Citation
Torres-Vergara P, Escudero C and Penny J (2018) Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives. Front. Physiol. 9:1502. doi: 10.3389/fphys.2018.01502
Received
20 July 2018
Accepted
05 October 2018
Published
06 November 2018
Volume
9 - 2018
Edited by
Qiaobing Huang, Southern Medical University, China
Reviewed by
Carmen Clapp, Universidad Nacional Autónoma de México, Mexico; Yong Gu, Southern Medical University, China
Updates
Copyright
© 2018 Torres-Vergara, Escudero and Penny.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pablo Torres-Vergara, pabltorr@udec.cl
This article was submitted to Vascular Physiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.